AIToday
AI in HealthcareTop Companies' AI MovesAI Business & IndustryTop Companies AIPublished: Nov 20, 2026, 06:31 JST

Pfizer aims to halve drug R&D timelines with AI, CSO says

Send on LINE
Pfizer aims to halve drug R&D timelines with AI, CSO says

3 Key Points

  1. What happened

    Pfizer CSO Chris Boshoff said the company aims to cut first-in-human time from roughly four years to two, and then halve Phase 1 to approval, building AI into its R&D decision cycles.

  2. Why it matters

    If achieved, halving these timelines could bring medicines to patients years sooner and reshape how the company prioritizes its pipeline, though the targets remain goals rather than results.

WHO IT HITSPfizer's R&D scientists and safety staff are the immediate users, with over 15,000 R&D colleagues already using AI tools and safety scientists handling more than 100,000 submissions a month. Patients waiting for new medicines could feel the effect if the timeline goals are met.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, every morning.

Context & Analysis

Pfizer's push is framed around what it calls decision cycles, not generic productivity. Drug development, as Boshoff describes it, is a race measured in decisions: whether a target, molecule or dose is right, which populations to study, and whether to keep going or stop. Evidence for those calls has historically been assembled by disconnected digital systems, debated in committees and handed between teams over months. The company's stated goal is to turn days or weeks of evidence assembly into answers it can act on in hours.

The foundation for that is data. Pfizer says its scientists have generated petabytes of proprietary data over decades, much of it archived across different systems after serving its original purpose. The company is now curating and standardizing that data, connecting it across sources and ensuring every result can be traced back to its origin, so that past evidence can inform the next decision. Boshoff describes the vision as an R&D enterprise that learns at the rate of evidence and reasons from a shared platform.

Pfizer is also staffing up for the effort. Arpita Saha recently joined as its first Chief R&D AI Officer after AI leadership roles at Tempus and Google, and Eric Schadt is working with the company as its R&D AI Scholar. Alongside internal work, Pfizer has a license agreement with Chai Discovery for the design of antibodies and other biologics, and a partnership with Cartography to identify potential novel targets for biologics.

FAQ
What is Pfizer's specific timeline goal?
Pfizer aims to cut the journey to first-in-human testing from roughly four years to two, and then halve the time from Phase 1 to approval.
Who is leading Pfizer's AI R&D effort?
Arpita Saha recently joined as Pfizer's first Chief R&D AI Officer, following AI leadership roles at Tempus and Google, and Eric Schadt is working with Pfizer as its R&D AI Scholar.
How many Pfizer R&D colleagues are using AI tools?
More than 15,000 R&D colleagues are using AI tools, according to the company.
Top Companies AIRead Original Article
Send on LINE

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.

Questions and answers are published on this page.

Related Articles

Next articleJX金属 shares sink 7.36% as copper, AI bets unwind